Barclays PLC Aura Biosciences, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 61,010 shares of AURA stock, worth $502,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,010

Previous 61,010 -0.0%

Holding current value

$502,112

Previous $544,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$6.9 - $10.36 $302,889 - $454,772	43,897 Added 256.51%	61,010 $544,000
Q2 2024 Aug 14, 2024	SELL	$6.81 - $7.89 $56,393 - $65,337	-8,281 Reduced 32.61%	17,113 $129,000
Q1 2024 May 15, 2024	SELL	$7.09 - $9.24 $90,574 - $118,041	-12,775 Reduced 33.47%	25,394 $199,000
Q4 2023 Feb 15, 2024	BUY	$7.02 - $11.98 $233,730 - $398,874	33,295 Added 683.11%	38,169 $338,000
Q3 2023 Nov 07, 2023	SELL	$8.97 - $12.38 $206,112 - $284,467	-22,978 Reduced 82.5%	4,874 $43,000
Q2 2023 Aug 03, 2023	SELL	$8.51 - $13.33 $55,868 - $87,511	-6,565 Reduced 19.07%	27,852 $344,000
Q1 2023 May 04, 2023	SELL	$8.88 - $12.11 $18,665 - $25,455	-2,102 Reduced 5.76%	34,417 $320,000
Q4 2022 Feb 13, 2023	SELL	$9.86 - $14.59 $54,476 - $80,609	-5,525 Reduced 13.14%	36,519 $384,000
Q3 2022 Nov 03, 2022	SELL	$13.1 - $20.34 $1,860 - $2,888	-142 Reduced 0.34%	42,044 $762,000
Q2 2022 Aug 12, 2022	SELL	$12.37 - $21.86 $216,611 - $382,790	-17,511 Reduced 29.33%	42,186 $598,000
Q1 2022 May 16, 2022	BUY	$15.94 - $23.34 $951,570 - $1.39 Million	59,697 New	59,697 $1.31 Million

Others Institutions Holding AURA

# of Institutions

Shares Held

37.6M

Call Options Held

122K

Put Options Held

38.5K

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $241M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account